SEC Filing Summary: AntriaBio, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AntriaBio, Inc. on July 25, 2017. The filing serves as a Regulation FD disclosure, referencing a press release issued on the same date (Exhibit 99.1). The registrant is incorporated in Delaware with principal executive offices in Louisville, CO.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural disclosure of a press release rather than a financial statement.
Material Changes
No material financial changes or comparative period data are detailed within the body of this Form 8-K. The document solely references the attached press release for the substance of the disclosure.
Guidance, Outlook, and Risks
The filing explicitly states that the information is "furnished" and not "filed" for purposes of the Securities Exchange Act of 1934. Consequently, the text does not contain management commentary, guidance, or risk factors within the report itself; these details are contained in the referenced Exhibit 99.1 press release.
Key Facts for Investor Verification
- Verify the content of the press release attached as Exhibit 99.1, as the 8-K body contains no substantive operational or financial data.
- Note that the disclosure is furnished under Regulation FD and is not deemed "filed" for liability purposes under the Exchange Act.
- Confirm the company name is AntriaBio, Inc., despite the request metadata referencing "Rezolute, Inc."